Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing PerspectivesLuisa Carbognin, Maria Vittoria Dieci, Federica Miglietta et al.|Cancers|2019Cited by 115
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?Giovanna Garufi, Fabio Puglisi, Luisa Carbognin et al.|Cancer Treatment Reviews|2022Cited by 20
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapyGiovanna Garufi, Emilio Bria, Luisa Carbognin et al.|Therapeutic Advances in Medical Oncology|2023Cited by 11
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluationMaria Vittoria Dieci, Valentina Guarneri, Luisa Carbognin et al.|British Journal of Cancer|2022Cited by 9
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapyLuca Mastrantoni, Emilio Bria, Giovanna Garufi et al.|npj Breast Cancer|2025Cited by 9